Viridian Therapeutics Details $250M Concurrent Offerings of Convertible Notes and Equity

summarizeSummary

Viridian Therapeutics filed a preliminary prospectus supplement for concurrent offerings to raise $250 million through $150 million in convertible senior notes and $100 million in common or preferred stock, aimed at repaying debt and funding R&D.

check_boxKey Events

• Convertible Senior Notes Offering Detailed

  The company is offering $150.0 million aggregate principal amount of convertible senior notes due 2032. The offering includes an over-allotment option for an additional $22.5 million. The interest rate and initial conversion price are not yet specified in this preliminary filing.

• Concurrent Equity Offering Announced

  Concurrently with the notes, Viridian is conducting a public offering of $100.0 million in common stock or Series B non-voting convertible preferred stock, with an over-allotment option for an additional $15.0 million. This offering is being made pursuant to a separate prospectus supplement.

• Total Capital Raise of $250 Million

  The combined offerings aim to raise an initial aggregate of $250.0 million, potentially increasing to $287.5 million if over-allotment options for both offerings are fully exercised. This follows the FWP announcement on May 5, 2026, of the intent to raise $250 million.

• Use of Proceeds Outlined

  Net proceeds will be used to repay $50.4 million in outstanding secured indebtedness under the Hercules Loan and Security Agreement, fund market expansion studies for its Thyroid Eye Disease (TED) franchise, advance earlier pipeline research and development, and for general corporate purposes.

auto_awesomeAnalysis

This preliminary prospectus supplement formalizes the details of a substantial capital raise, previously announced in an FWP, totaling $250 million through a combination of convertible senior notes and a concurrent equity offering. This financing is critical for Viridian Therapeutics, a life sciences company, as it aims to repay existing secured debt and fund ongoing research and development, particularly for its Thyroid Eye Disease (TED) franchise and earlier pipeline candidates. While the capital infusion provides a necessary runway for operations and product development, especially following recent positive clinical data, the significant dilutive potential from both the convertible notes and the equity offering warrants investor attention. The exact interest rate and conversion price for the notes, and the pricing for the equity offering, are still pending, which will determine the final economic impact on shareholders. Investors should monitor the final terms of these offerings for a complete assessment of their impact.